OxThera initiates extension part of a Phase 3 study of Oxabact in Primary Hyperoxaluria
STOCKHOLM, SWEDEN – June 20, 2019. OxThera AB, a biopharmaceutical company dedicated to improve the lives of people living with Primary Hyperoxaluria, today announced that the first patients in a Phase 3 study of Oxabact® have completed the study and transitioned to an open-label extension part. All clinics participating in the study will continue to treat patients in the extension part for another two years. Topline results from the Phase 3 study are expected in the first quarter of 2021.Primary Hyperoxaluria is a rare autosomal recessive disorder leading to markedly elevated levels of